Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation-Cancer Interface

• Published in: Cancers Vol. 15; no. 11; p. 2895
• Main Authors: Stone, Trevor W, Williams, Richard O
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.05.2023; MDPI
• Subjects: Amino acids; Antigens; Apoptosis; Cancer; Cell cycle; Cell growth; Cytokines; Development and progression; Dioxygenase; Disease susceptibility; Enzymes; Genotype & phenotype; Hypoxia; Immune system; Immunological tolerance; Immunosuppressive agents; Inflammation; Ipilimumab; Kinases; Ligands; Lymphocytes; Metabolism; Metabolites; Physiological aspects; Prevention; Proteins; Review; Reviews; Therapeutic targets; Transcription factors; Transduction; Tryptophan; Tumors; kynurenine; IDO2; kynurenic acid; TDO; IDO1; indoleamine-2,3-dioxygenase
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15112895

The mechanisms underlying a relationship between inflammation and cancer are unclear, but much emphasis has been placed on the role of tryptophan metabolism to kynurenine and downstream metabolites, as these make a substantial contribution to the regulation of immune tolerance and susceptibility to cancer. The proposed link is supported by the induction of tryptophan metabolism by indoleamine-2,3-dioxygenase (IDO) or tryptophan-2,3-dioxygenase (TDO), in response to injury, infection or stress. This review will summarize the kynurenine pathway and will then focus on the bi-directional interactions with other transduction pathways and cancer-related factors. The kynurenine pathway can interact with and modify activity in many other transduction systems, potentially generating an extended web of effects other than the direct effects of kynurenine and its metabolites. Conversely, the pharmacological targeting of those other systems could greatly enhance the efficacy of changes in the kynurenine pathway. Indeed, manipulating those interacting pathways could affect inflammatory status and tumor development indirectly via the kynurenine pathway, while pharmacological modulation of the kynurenine pathway could indirectly influence anti-cancer protection. While current efforts are progressing to account for the failure of selective IDO1 inhibitors to inhibit tumor growth and to devise means of circumventing the issue, it is clear that there are wider factors involving the relationship between kynurenines and cancer that merit detailed consideration as alternative drug targets.